The Crosstalk between GPR81/IGFBP6 Promotes Breast Cancer Progression by Modulating Lactate Metabolism and Oxidative Stress.

GPR81 IGFBP6 breast cancer lactate oxidative stress

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
29 Jan 2022
Historique:
received: 30 12 2021
revised: 24 01 2022
accepted: 26 01 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Breast cancer is the most frequent tumor and the leading cause of cancer deaths in women. In recent years, lactate metabolism and, in particular, its receptor GPR81 have been shown to play a vital role in cancer biology. GPR81 is upregulated in breast cancer and promotes tumor growth by tumor cell-derived lactate. Therefore, the search for possible crosstalk and the involvement of new molecules capable of generating this pathology is always in continuous development. In this study, the relationship between GPR81 and IGFBP6 protein in tumor growth and oxidative stress in the human breast cancer cell line MDA-MB-231 was studied. Cells were treated with lactate or the GPR81 receptor agonist and antagonist 3,5-DHBA and 3-OBA, respectively. In addition, oxidative stress and proliferation were also evaluated in cells challenged with the recombinant IGFBP6 protein. Our data showed that lactate induced cell proliferation and wound healing of the MDA-231 breast cancer cell through the overexpression of both the lactate receptor GPR81 and IGFBP6. The increase in IGFBP6 was able, in turn, to improve the mitochondrial fitness and redox state, as suggested by the reduced levels of mitochondrial ROS production after IGFBP6 treatment, presumably mediated by the increase in the ROS detoxifying genes HMOX1, GSTK1 and NQO1. In conclusion, our data highlight a novel axis between GPR81 and IGFBP6 in MDA-231 cells able to modulate lactate metabolism and oxidative stress. This complex signaling may represent a new therapeutic target for breast cancer.

Identifiants

pubmed: 35204157
pii: antiox11020275
doi: 10.3390/antiox11020275
pmc: PMC8868469
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
Oncotarget. 2016 Oct 25;7(43):70898-70911
pubmed: 27765922
CNS Neurosci Ther. 2015 Mar;21(3):271-9
pubmed: 25495836
Curr Pharm Des. 2014;20(30):4879-98
pubmed: 24283956
Ann Agric Environ Med. 2017 Dec 23;24(4):549-553
pubmed: 29284222
Biomolecules. 2020 Apr 30;10(5):
pubmed: 32365811
Cancer Treat Res. 2019;178:45-80
pubmed: 31209841
Cell Cycle. 2013 May 1;12(9):1371-84
pubmed: 23574725
Growth Horm IGF Res. 2016 Oct - Dec;30-31:81-86
pubmed: 27681092
Cell Cycle. 2012 Apr 1;11(7):1445-54
pubmed: 22395432
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2014 Sep 15;74(18):5301-10
pubmed: 24928781
Pharmacol Ther. 2020 Feb;206:107451
pubmed: 31836453
Stem Cells Int. 2019 Feb 17;2019:9245938
pubmed: 30911300
Front Immunol. 2016 Feb 16;7:52
pubmed: 26909082
Front Oncol. 2020 Dec 21;10:604143
pubmed: 33409153
Cancer Res. 2011 Apr 1;71(7):2550-60
pubmed: 21300765
Oncogene. 2020 Apr;39(16):3292-3304
pubmed: 32071396
Brain Res. 2020 Nov 1;1746:146945
pubmed: 32531223
J Cell Biochem. 1993 Jun;52(2):196-205
pubmed: 7690042
Clin Sci (Lond). 2013 Feb;124(4):215-29
pubmed: 23126425
Curr Pharm Des. 2012;18(10):1319-30
pubmed: 22360558
FEBS J. 2007 Mar;274(6):1393-418
pubmed: 17302740
Oxid Med Cell Longev. 2018 Feb 28;2018:2426712
pubmed: 29682155
Mol Med Rep. 2020 Sep;22(3):1727-1736
pubmed: 32582969
J Cell Commun Signal. 2015 Jun;9(2):189-200
pubmed: 25808083
J Immunol. 2013 Aug 1;191(3):1486-95
pubmed: 23817426
Trends Biochem Sci. 2019 Feb;44(2):153-166
pubmed: 30473428
Cancer Cell. 2006 Jun;9(6):425-34
pubmed: 16766262

Auteurs

Lucia Longhitano (L)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Stefano Forte (S)

IOM Ricerca Srl, 95029 Viagrande, Italy.

Laura Orlando (L)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Stephanie Grasso (S)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Alessandro Barbato (A)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Nunzio Vicario (N)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Rosalba Parenti (R)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Paolo Fontana (P)

IOM Ricerca Srl, 95029 Viagrande, Italy.

Angela M Amorini (AM)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Giuseppe Lazzarino (G)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Giovanni Li Volti (G)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Michelino Di Rosa (M)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Arcangelo Liso (A)

Department of Medical and Surgical Sciences, University of Foggia, 71100 Foggia, Italy.

Barbara Tavazzi (B)

UniCamillus-Saint Camillus International University of Health Sciences, Via di Sant'Alessandro 8, 00131 Rome, Italy.

Giacomo Lazzarino (G)

UniCamillus-Saint Camillus International University of Health Sciences, Via di Sant'Alessandro 8, 00131 Rome, Italy.

Daniele Tibullo (D)

Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

Classifications MeSH